Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool

Ryan P Topping, PhD, Kristen Rosenthal, PhD, Farrukh T Awan, MD, Jennifer R Brown, MD PhD, Nicole Lamanna, MD, Jeff P Sharman, MD, Timothy A Quill, PhD, Andrew D Zelenetz, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141082

Published: 2020

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

Journal Articles

A Radiomic Machine Learning Model to Predict Treatment Response to Methotrexate and Survival Outcomes in Primary Central Nervous System Lymphoma (PCNSL)

Omer M Ali, MD, Sahil S Nalawade, MS, Yin Xi, PhD, Ben Wagner, BM, Alexander Mazal, MD, Shane Ahlers, MD, Syed M Rizvi, MD, Farrukh T Awan, MD, Kiran A Kumar, MD MBA, Neil B Desai, MD MHS, Joseph A Maldjian, MD, Marco C Pinho, MD, Praveen Ramakrishnan Geethakumari, MD MS

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141941

Published: 2020

Journal Articles

CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy

Revathi Ravella, BA, Elizabeth Ren Zhang-Velten, MD PhD, Farrukh T Awan, MD, Syed M Rizvi, MD, Jennifer L Shah, MD, Neil B Desai, MD MHS, Praveen Ramakrishnan Geethakumari, MD MS, Kiran A Kumar, MD MBA

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141445

Published: 2020

Journal Articles

Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations

Kristen Rosenthal, PhD, Jeremy S Abramson, MD MMSc, Farrukh T Awan, MD, John P. Leonard, MD, Julie M. Vose, MD MBA, Timothy A Quill, PhD, Christopher Flowers, MDMS

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-139818

Published: 2020

Journal Articles

Comparison of Demographics, Treatment Patterns and Outcomes Among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution within the Same Healthcare System

Akshat M Patel, Omer M Ali, MD, Radhika Kainthla, MD, Syed M Rizvi, MD, Farrukh T Awan, MD, Neil B Desai, MD MHS, Robert Timmerman, MD, Kiran A Kumar, MD MBA, Praveen Ramakrishnan Geethakumari, MD MS

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138568

Published: 2020

Journal Articles

Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team

Lauren Willis, PharmD, Lisa Brauer, PhD, Emily S Van Laar, MS, Patrick Kugel, MBA, Katie S Lucero, PhD MS, BS, John N. Allan, MD, Farrukh T. Awan, MD, Danielle M. Brander, MD, Jonathon B. Cohen, MDMS, Jacqueline C Barrientos, MD

Blood (2019) 134 (Supplement_1): 5878.

https://doi.org/10.1182/blood-2019-124808

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD

Blood (2019) 134 (Supplement_1): 3045.

https://doi.org/10.1182/blood-2019-124538

Published: 2019

Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Blood (2019) 134 (Supplement_1): 3039.

https://doi.org/10.1182/blood-2019-128706

Published: 2019

Journal Articles

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

David Andorsky, MD, Rebecca J Chan, MD PhD, Jamyia Clark, MPH, Bianca Ruzicka, PhD, Nicholas James Robert, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 2810.

https://doi.org/10.1182/blood-2019-124013

Published: 2019

Journal Articles

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Jennifer Woyach, MD, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Eric McLaughlin, MS, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Michael Keller, Matthew Dort, Gerard Lozanski, MD, Barbara Andersen, PhD, John C. Byrd, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 1759.

https://doi.org/10.1182/blood-2019-131099

Published: 2019

Journal Articles

Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia

Bing-E Xu, PhD, Kristen M Rosenthal, PhD, Krista Marcello, BA, Farrukh T. Awan, MD, Steven Coutre, MD, Nicole Lamanna, MD, Jeff P. Sharman, MD, Timothy A Quill, PhD, Kevin L Obholz, PhD, Andrew D. Zelenetz, MD PhD

Blood (2019) 134 (Supplement_1): 4724.

https://doi.org/10.1182/blood-2019-129266

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Tyler Dickerson, PharmD, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Devin Haddad, Avirup Guha, Kyle Porter, Kerry A. Rogers, MD, Jennifer A. Woyach, MD, John C. Byrd, MD, Daniel Addison, Farrukh T. Awan, MD MS

Blood (2018) 132 (Supplement 1): 4423.

https://doi.org/10.1182/blood-2018-99-110345

Published: 2018

Journal Articles

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Kami J. Maddocks, MD, Farrukh T. Awan, MD MS, Ying Huang, MA, MS, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MD MS, Samantha Jaglowski, MD MPH, Basem M. William, MRCP, MD, Kristie A. Blum, MD, Beth A. Christian, MD

Blood (2018) 132 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2018-99-117172

Published: 2018

Journal Articles

Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States

Blood (2018) 132 (Supplement 1): 4414.

https://doi.org/10.1182/blood-2018-99-112971

Published: 2018

Journal Articles

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, PhD, Farrukh T. Awan, MD MS, Corrinne Hoffman, CNP, Kami J. Maddocks, MD, Mark Reid, CNP, Jennifer A. Woyach, MD, Thomas Whitlow, BA, Jeffrey A. Jones, MD MPH, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 693.

https://doi.org/10.1182/blood-2018-99-114169

Published: 2018

Journal Articles

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Farrukh T. Awan, MD MS, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 5322.

https://doi.org/10.1182/blood-2018-99-110477

Published: 2018

Journal Articles

Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment

Elizabeth Kander, MD, Qiuhong Zhao, MS, Tracy Wiczer, John C. Byrd, MD, Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Tzu-Fei Wang, MD

Blood (2018) 132 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2018-99-110556

Published: 2018

NARROW

Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

A Radiomic Machine Learning Model to Predict Treatment Response to Methotrexate and Survival Outcomes in Primary Central Nervous System Lymphoma (PCNSL)

CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy

Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations

Comparison of Demographics, Treatment Patterns and Outcomes Among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution within the Same Healthcare System

Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only